Cytiva acquired Intermountain Life Sciences, a manufacturer of high-purity water, buffers, and liquid cell-culture media. Cytiva will use Intermountain’s manufacturing site in Logan, Utah to boost its liquid cell-culture production by millions of liters.

“The demand for buffers and cell culture media has grown substantially in recent years thanks to their use in gene therapies, as well as their use in making COVID-19 vaccines and therapies,” says Olivier Loeillot, vice president for Cytiva. “Adding the capacity and talent from Intermountain Life Sciences will allow us to accelerate deliveries to our customers.”

Intermountain’s site is already fully functional and running. Cytiva intends to ramp up production through additional hiring. “We’re really impressed with the quality practices that we see, and we’ll be bringing dozens of people on board to build on the work already being done at the site,” adds Loeilllot.

Process liquid products are experiencing rapid growth, and customers are shifting from internal production capabilities to outsourcing, according to a Cytiva spokesperson. The Intermountain site and its capabilities will become part of Cytiva’s cell-culture media portfolio, which has a 40-plus year history in the Cache Valley and currently employs more than 700 people at its Logan facilities.

Intermountain Life Sciences was established in 2014 as a cGMP facility for manufacturing water for pharmaceutical purposes and custom process solutions for use in a broad spectrum of scientific research, medical device, and biopharmaceutical manufacturing applications.

Previous articleThe Power of Ultra-Long Reads
Next articlePredicting TCR Specificity with Multiomic Single-Cell Sequencing